Novartis site directory
Research & Development
Access To Healthcare
Who We Are
Annual Report 2016
Share Data & Analysis
Working at Novartis
Awards & Recognition
Diversity & Inclusion
Compensation & Benefits
Careers in Research
The STEP Program
Six-year pivotal study data reinforce the superiority of Tasigna® over
® in newly-diagnosed patients with Ph+ CML
Fewer patients on Tasigna vs.
had their leukemia progress to advanced stage, a key goal of treatment ... confirm the favorable risk/benefit profile of Tasigna vs.
in newly-diagnosed CML patients Basel, December 8, 2014 - ... the superiority of Tasigna ® (nilotinib) compared to
® (imatinib)[*] at achieving higher rates of early, deep and ...
Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna® from
... chronic myeloid leukemia (CML) patients who switched from
® (imatinib)* due to intolerance, resistance or physician ... had not achieved and sustained this response previously with
,. Results of this post-hoc analysis were presented today in an ...
Novartis Oncology Access
... Novartis. Full donation of certain products. The
International Patient Assistance Program Recognizing from the ... success. In 2002, Novartis Oncology introduced the
International Patient Assistance Program (GIPAP TM ), providing ...
Novartis a réalisé un troisième trimestre solide, les produits de croissance ayant compensé l'expiration du brevet de
; plusieurs résultats positifs concernant des blockbusters potentiels
... de pourcentage, principalement en raison du générique de
/Gleevec aux Etats-Unis. Les produits de croissance ont progressé de ... de croissance ayant compensé l'expiration du brevet de
; plusieurs résultats positifs concernant des blockbusters potentiels ...
Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna®
... 57.9% of eligible patients who had switched to Tasigna from
® maintaining TFR for 48 weeks after treatment cessation ... both in the first-line setting and after switching from
(imatinib)*,. Discussions with regulatory authorities are underway ...
Novartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product label
... in both the first-line setting and after switching from
® Addition of TFR data to label provides patients and ... in both in the first-line setting and after switching from
® (imatinib)*,. No new major safety findings were observed in ...
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
CMLPath to Care(TM) collaboration replaces
International Patient Access Program (GIPAP) with a new, independent, ... to care for patients in lower-income countries through the
International Patient Assistance Program (GIPAP), one of the most ...
Novartis data shows half of eligible Ph+ CML-CP patients remain in Treatment-free Remission nearly two years after stopping Tasigna®
... achieved a sustained DMR with Tasigna after switching from
[®] (imatinib)*, respectively. "The findings from the 96-week ... at least three years of Tasigna therapy, but not with prior
therapy, found that more than half (53.2%) of patients were able to ...
Charles L. Sawyers, M.D.
... researcher, he co-developed the Novartis cancer drug Gleevec/
and has received numerous honors and awards, including the ...
... % change (cc) 2016 franchise Gleevec/
3,323 -28% Oncology Gilenya 3,109 14% ...
© 2017 Novartis AG
This site is intended for a global audience.